DWTX8:45 AMDogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension StudyTrial Start • Phase 2Trial initiation Mon, May 18, 2026, 8:45 AM EDTGvirios.com
DWTX8:30 AMDogwood Therapeutics Announces First Quarter 2026 Financial ResultsEnrollment • Phase 2virios.com
DWTX8:30 AMDogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026virios.com
DWTX9:00 AMDogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100Mvirios.com
DWTX9:00 AMDogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathyvirios.com
DWTX8:30 AMDogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Resultsvirios.com